Summary
EV-201 was a multicentre, single-arm phase 2 trial evaluating enfortumab vedotin in cisplatin-ineligible patients with advanced urothelial carcinoma who had experienced disease progression following PD-1 or PD-L1 inhibitor therapy. As suggested by the trial design and publication in The Lancet Oncology (2021), the study likely reports efficacy outcomes and safety data for this patient population, though without access to the full text, specific effect sizes and conclusions cannot be stated with certainty.
UK applicability
If enfortumab vedotin demonstrates clinical benefit in this trial, findings would be relevant to UK oncology practice, subject to National Institute for Health and Care Excellence appraisal and NHS commissioning decisions. However, applicability depends on trial outcomes, trial conduct sites, and alignment with UK-standard immunotherapy sequencing.
Key measures
Objective response rate, duration of response, adverse event incidence and grading (as typical for oncology phase 2 trials)
Outcomes reported
The study assessed clinical efficacy and safety of enfortumab vedotin (a Nectin-4-directed ADC) in cisplatin-ineligible patients with advanced urothelial carcinoma who had progressed on or after PD-1/PD-L1 inhibitor therapy. Efficacy endpoints likely included objective response rate, duration of response, and progression-free or overall survival; safety profiling included adverse event incidence and severity.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.